RxSight Stock Sees Relative Strength Rating Rise To 91

On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91.

IBD's proprietary rating identifies price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.

History shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they begin their biggest climbs.

Here Are 3 Keys For Successful Stock Investing

Is RxSight Stock A Buy?

RxSight stock recently reclaimed its 50-day moving average. While the medical stock is not near an ideal buy point right now, see if it goes on to form and break out from a proper consolidation.

The medical device company posted 0% EPS growth in its most recent report, while sales growth came in at 68%.

RxSight stock earns the No. 22 rank among its peers in the Medical-Products industry group. United-Guardian, ResMed and TransMedics Group are among the top 5 highly rated stocks within the group.